Tiziana Life Sciences PLC

("Tiziana" or the "Company")

 

 

Statement re broker

The Company notes the announcement today regarding Beaufort Securities Limited ("BSL") and Beaufort Asset Clearing Services Limited ("BACSL") being placed into insolvency and that the Financial Conduct Authority (the "FCA") has imposed requirements on BSL and BACSL to cease all regulatory activity.

BSL is the broker to the Company pursuant to the AIM Rules for Companies (the "AIM Rules").  As a result of the requirements imposed by the FCA, BSL will no longer be able to provide broking services to the Company in accordance with the AIM Rules.

The Company is seeking to appoint a new broker as soon as possible and a further announcement will be made when this appointment is made.

 

 

Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder	+44 (0)20 7493 2853
Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner / Richard Nash	+44 (0)20 7213 0880

 

 

 

 

About Tiziana

 

Tiziana is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound milciclib. The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered human anti-CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

 

For more information go to http://www.tizianalifesciences.com